J Endocr Surg.  2018 Sep;18(3):210-213. 10.16956/jes.2018.18.3.210.

Duodenal Neuroendocrine Tumor: a Diagnostic Surprise during Workup for Anemia

• Patel MS
• Akula B
• Veer S
• Deshpande

• KMID: 2420779
• DOI: http://doi.org/10.16956/jes.2018.18.3.210

Abstract

Neuroendocrine tumors (NETs) arising from the pancreas and duodenum together represent 18% of all gastroenteropancreatic NETs. Duodenal neuroendocrine tumor (D-NET) comprises 1%-3% of all primary duodenal tumors, of these only 20% are resectable. Surgery remains the only curative option provided a R0 resection can be done. We present a case of D-NET in an elderly male who was being investigated for anemia who was treated with pancreaticoduodenectomy and was discharged without sequele.

Keyword

Duodenal neuroendocrine tumor; WHO classification; Pancreaticoduodenectomy; Anemia

MeSH Terms

Aged
Anemia*
Duodenum
Humans
Male
Neuroendocrine Tumors*
Pancreas
Pancreaticoduodenectomy

Figure

• 

  Fig. 1 CT scan showing nodal lesion at the junction of D1 and D2 (white arrow). CT = computed tomography.

• 

  Fig. 2 Operative specimen of the pancreaticoduodenectomy.

Reference

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26:3063–3072.

2. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005; 19:675–697.

3. Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol. 2007; 102:1464–1473.

4. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009; 249:63–71.

5. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008; 87:8–19.

6. Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Müller M, et al. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013; 13:63–72.

7. Kim MK. Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors. Gut Liver. 2012; 6:405–410.

8. Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016; 103:119–124.

9. Barber TW, Hofman MS, Thomson BN, Hicks RJ. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012; 38:64–71.